Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula:

##STR00001##

or a salt therof. R.sub.1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R.sub.2 is —N.sup.+H.sub.3, —N.sup.+H.sub.2Z, —N.sup.+HZ.sub.2, or —N.sup.+Z.sub.3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.

Alkylphosphocholine analogs incorporating a chelating moiety that is chelated to gadolinium are disclosed herein. The alkylphophocholine analogs are compounds having the formula:

##STR00001##

or a salt therof. R.sub.1 includes a chelating agent that is chelated to a gadolinium atom; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R.sub.2 is —N.sup.+H.sub.3, —N.sup.+H.sub.2Z, —N.sup.+HZ.sub.2, or —N.sup.+Z.sub.3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2. The compounds can be used to detect solid tumors or to treat solid tumors. In detection/imaging applications, the gadolinium emits signals that are detectable using magnetic resonance imaging. In therapeutic treatment, the gadolinium emits tumor-targeting charged particles when exposed to epithermal neutrons.

The present invention provides a compound represented by formula (I) or formula (II) capable of reducing the color difference before and after post-baking.

##STR00001##

[In the formula (I), R.sup.1 represents a C2-C20 unsaturated hydrocarbon group optionally having a substituent; R.sup.2 represents a hydrogen atom, a C1-C20 hydrocarbon group optionally having a substituent, or a single bond connecting Z.sup.2 and R.sup.1; and Z.sup.1 and Z.sup.2 each independently represent a single bond or an oxygen atom, and in the formula (II), R.sup.3 represents a C2-C20 unsaturated hydrocarbon group optionally having a substituent; and Z.sup.3 represents a single bond or an oxygen atom].

The present invention provides a compound represented by formula (I) or formula (II) capable of reducing the color difference before and after post-baking.

##STR00001##

[In the formula (I), R.sup.1 represents a C2-C20 unsaturated hydrocarbon group optionally having a substituent; R.sup.2 represents a hydrogen atom, a C1-C20 hydrocarbon group optionally having a substituent, or a single bond connecting Z.sup.2 and R.sup.1; and Z.sup.1 and Z.sup.2 each independently represent a single bond or an oxygen atom, and in the formula (II), R.sup.3 represents a C2-C20 unsaturated hydrocarbon group optionally having a substituent; and Z.sup.3 represents a single bond or an oxygen atom].

Here we show that P. ananatis produces at least three phosphonates, two of which were purified and structurally characterized. The first, designated pantaphos, was shown to be 2-(hydroxy(phosphono)methyl)maleate; the second, a probable biosynthetic precursor, was shown to be 2-(phosphonomethyl)maleate. Purified pantaphos is both necessary and sufficient for the hallmark lesions of onion center rot. Moreover, when tested against mustard seedlings, the phytotoxic activity of pantaphos was comparable to the widely used herbicides glyphosate and phosphinothricin. Pantaphos was also active against a variety of human cell lines.

##STR00001##

The present invention relates to compounds of general formula (I), wherein —X is selected from a group consisting of H; C.sub.1 to C.sub.6, alkyl; halogen (F, Cl, Br or I); Y is selected from a group consisting of nitrogen; N-oxide; Z.sup.1, Z.sup.2, Z.sup.m, wherein m is 1 or 2, are independently selected from the group consisting of —CH.sub.2—CH.sub.2— and —CH.sub.2—CH.sub.2—CH.sub.24 A, A.sup.m, wherein m is 1 or 2, are independently selected from H; —CH.sub.2COOH; —CH.sub.2C(O)NH.sub.2; —CH.sub.2P(O)(OH).sub.2, and n is 1 or 2; R.sup.1, R.sup.2, R.sup.3 are independently H; C.sub.1 to C.sub.6, alkyl; C.sub.1 to C.sub.6 alkyloxy; C.sub.6 to C.sub.10 aryloxy; benzyloxy; C.sub.1 to C.sub.6 alkylthio; C.sub.6, to C.sub.10 arylthio; F; Cl; Br; I; OH; SH; NH.sub.2; C.sub.1 to C.sub.6, alkylamino; di(C.sub.1 to C.sub.6, alkyl)amino; C.sub.1 to C.sub.6 acylamino; di(C.sub.1 to C.sub.6 acyl) amino; C.sub.6 to C.sub.10 arylamino; di(C.sub.6 to C.sub.10 aryl)amino; CN; OH; nitro; COOR.sub.n, C(O)NHR.sub.n, C(O)N(R.sub.n).sub.2, wherein R.sub.n is independently H or C.sub.1 to C.sub.10 alkyl or C.sub.6, to C.sub.10 aryl; and/or neighboring two of R.sup.1, R.sup.2, R.sup.3 together with neighboring two carbon atoms of the aromatic cycle form a six-membered ring, optionally substituted with one or more substituents independently selected from the group consisting of OH, SH, CF.sub.3, F, Cl, Br, I, C.sub.1 to C.sub.6, alkyl, C.sub.1to C.sub.6, alkyloxy, C.sub.1 to C.sub.6 alkylthio, NH.sub.2, C.sub.1 to C.sub.6 alkylamino, di(C.sub.1 to C.sub.6 alkyl)amino, NO.sub.2, COOH, COOR.sub.n, C(O)NHR.sub.n, C(O)N(R.sub.n).sub.2, wherein R.sub.n is WO 2020/244686 A1 independently H or C.sub.1 to C.sub.10 alkyl or C.sub.6 to C.sub.10 aryl; with the proviso that when n is 2 and all of Z.sup.1, Z.sup.2, Z.sup.m are —CH.sub.2—CH.sub.2—, then A is not —CH.sub.2COOH; for chromatographic separation of rare earth elements and/or s-, p- and d-block metals, as well as to the method of the separation of rare earth elements.

##STR00001##

The present invention relates to compounds of general formula (I), wherein —X is selected from a group consisting of H; C.sub.1 to C.sub.6, alkyl; halogen (F, Cl, Br or I); Y is selected from a group consisting of nitrogen; N-oxide; Z.sup.1, Z.sup.2, Z.sup.m, wherein m is 1 or 2, are independently selected from the group consisting of —CH.sub.2—CH.sub.2— and —CH.sub.2—CH.sub.2—CH.sub.24 A, A.sup.m, wherein m is 1 or 2, are independently selected from H; —CH.sub.2COOH; —CH.sub.2C(O)NH.sub.2; —CH.sub.2P(O)(OH).sub.2, and n is 1 or 2; R.sup.1, R.sup.2, R.sup.3 are independently H; C.sub.1 to C.sub.6, alkyl; C.sub.1 to C.sub.6 alkyloxy; C.sub.6 to C.sub.10 aryloxy; benzyloxy; C.sub.1 to C.sub.6 alkylthio; C.sub.6, to C.sub.10 arylthio; F; Cl; Br; I; OH; SH; NH.sub.2; C.sub.1 to C.sub.6, alkylamino; di(C.sub.1 to C.sub.6, alkyl)amino; C.sub.1 to C.sub.6 acylamino; di(C.sub.1 to C.sub.6 acyl) amino; C.sub.6 to C.sub.10 arylamino; di(C.sub.6 to C.sub.10 aryl)amino; CN; OH; nitro; COOR.sub.n, C(O)NHR.sub.n, C(O)N(R.sub.n).sub.2, wherein R.sub.n is independently H or C.sub.1 to C.sub.10 alkyl or C.sub.6, to C.sub.10 aryl; and/or neighboring two of R.sup.1, R.sup.2, R.sup.3 together with neighboring two carbon atoms of the aromatic cycle form a six-membered ring, optionally substituted with one or more substituents independently selected from the group consisting of OH, SH, CF.sub.3, F, Cl, Br, I, C.sub.1 to C.sub.6, alkyl, C.sub.1to C.sub.6, alkyloxy, C.sub.1 to C.sub.6 alkylthio, NH.sub.2, C.sub.1 to C.sub.6 alkylamino, di(C.sub.1 to C.sub.6 alkyl)amino, NO.sub.2, COOH, COOR.sub.n, C(O)NHR.sub.n, C(O)N(R.sub.n).sub.2, wherein R.sub.n is WO 2020/244686 A1 independently H or C.sub.1 to C.sub.10 alkyl or C.sub.6 to C.sub.10 aryl; with the proviso that when n is 2 and all of Z.sup.1, Z.sup.2, Z.sup.m are —CH.sub.2—CH.sub.2—, then A is not —CH.sub.2COOH; for chromatographic separation of rare earth elements and/or s-, p- and d-block metals, as well as to the method of the separation of rare earth elements.

Applicants have developed an amplification system and methodology for IHC and ISH staining that utilizes “click chemistry” to covalently bind reporter molecules to tissue.

Applicants have developed an amplification system and methodology for IHC and ISH staining that utilizes “click chemistry” to covalently bind reporter molecules to tissue.

Dual-modality contrast agents are disclosed herein, having the general formula:

##STR00001##

R.sub.1 includes a chelating moiety that is chelated to a Mn.sup.2+ isotope. The disclosed contrast agents differentially target a wide range of malignant tumor tissues, and can be simultaneously used as contrast agents for both magnetic resonance imaging (MRI) and positron emission topography (PET) imaging. Accordingly, the disclosed contrast agent can be used in diagnosing and monitoring solid tumor cancers.